COMMON STOCK PURCHASE WARRANT SANGAMO THERAPEUTICS, INC.Common Stock Purchase Warrant • March 25th, 2024 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
This COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, the registered holder hereof or its permitted assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions set forth herein, at any time on or after the Issue Date and until 5:00 p.m., New York time, on the Expiration Date (but not thereafter), to subscribe for and purchase from Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares (the “Warrant Shares”) of the Company’s common stock, par value $0.01 per share (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is one of the Common Stock Purchase Warrants issued in connection with the transactions contemplated by that certain Securities Purchase Agreement, dated as of March 21, 2024, by and between the Company and the Holder (the “Purchase Agreement”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 25th, 2024 • Sangamo Therapeutics, Inc • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 21, 2024, between Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the purchasers identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SANGAMO THERAPEUTICS, INC. 24,761,905 Shares of Common Stock par value $0.01 per share Pre-Funded Warrants to Purchase up to 3,809,523 Shares of Common Stock Warrants to Purchase 28,571,428 Shares of Common Stock Placement Agent AgreementSangamo Therapeutics, Inc • March 25th, 2024 • Biological products, (no disgnostic substances) • New York
Sangamo Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell directly to various investors (each, an “Investor” and collectively, the “Investors”), pursuant to the terms of this Placement Agent Agreement (this “Agreement”) and the Securities Purchase Agreement in the form of Exhibit D attached hereto (the “Securities Purchase Agreement”) entered into with such Investors, an aggregate of 24,761,905 shares of common stock, par value $0.01 per share (the “Common Stock”), of the Company (the “Shares”), pre-funded warrants to purchase up to an aggregate of 3,809,523 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”) and warrants to purchase an aggregate of 28,571,428 shares of Common Stock of the Company (the “Warrants”). The Common Stock issuable upon the exercise of the Warrants are referred to herein as the “Warrant Shares” and the Common Stock issuable upon the exercise of the Pre-Funded Warrants are referred to
